SG11202006255UA - Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability - Google Patents
Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeabilityInfo
- Publication number
- SG11202006255UA SG11202006255UA SG11202006255UA SG11202006255UA SG11202006255UA SG 11202006255U A SG11202006255U A SG 11202006255UA SG 11202006255U A SG11202006255U A SG 11202006255UA SG 11202006255U A SG11202006255U A SG 11202006255UA SG 11202006255U A SG11202006255U A SG 11202006255UA
- Authority
- SG
- Singapore
- Prior art keywords
- intraocular
- medicine
- preventing
- disease associated
- vascular permeability
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018016911 | 2018-02-02 | ||
| PCT/JP2019/003573 WO2019151470A1 (en) | 2018-02-02 | 2019-02-01 | Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006255UA true SG11202006255UA (en) | 2020-07-29 |
Family
ID=67479734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006255UA SG11202006255UA (en) | 2018-02-02 | 2019-02-01 | Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20210113529A1 (en) |
| EP (1) | EP3747471A4 (en) |
| JP (1) | JPWO2019151470A1 (en) |
| KR (1) | KR20200116953A (en) |
| CN (1) | CN111683682A (en) |
| AU (1) | AU2019214265A1 (en) |
| BR (1) | BR112020015567A2 (en) |
| CA (1) | CA3089952A1 (en) |
| IL (1) | IL275603A (en) |
| JO (1) | JOP20200186A1 (en) |
| MA (1) | MA53098A (en) |
| MX (1) | MX2020007948A (en) |
| PH (1) | PH12020551015A1 (en) |
| RU (1) | RU2020128700A (en) |
| SG (1) | SG11202006255UA (en) |
| WO (1) | WO2019151470A1 (en) |
| ZA (1) | ZA202004327B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021148439A1 (en) * | 2020-01-21 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for stimulating cerebrovascular function |
| WO2021163355A1 (en) * | 2020-02-11 | 2021-08-19 | Arena Pharmaceuticals, Inc. | Formulations and methods of treating conditions related to the s1p1 receptor |
| CN113082031A (en) * | 2021-03-09 | 2021-07-09 | 温州医科大学附属眼视光医院 | Application of dopamine D1 and D2 receptor nonselective agonist in preparation of drugs for treating pathological angiogenesis of eyes |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1643983T3 (en) | 2003-06-24 | 2010-10-29 | Univ Connecticut | Methods of inhibiting vascular permeability and apoptosis |
| US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
| EP1798226A4 (en) | 2004-08-04 | 2009-06-17 | Taisho Pharmaceutical Co Ltd | Triazole derivative |
| GB0504544D0 (en) * | 2005-03-04 | 2005-04-13 | Novartis Ag | Organic compounds |
| WO2007089018A1 (en) | 2006-02-03 | 2007-08-09 | Taisho Pharmaceutical Co., Ltd. | Triazole derivative |
| JP5218737B2 (en) | 2006-02-06 | 2013-06-26 | 大正製薬株式会社 | Sphingosine-1-phosphate binding inhibitor |
| CA2648303C (en) * | 2006-04-03 | 2014-07-15 | Astellas Pharma Inc. | 5-[monocyclic(hetero)arylsubstituted-1,2,4-oxadliazol-3-yl]-(fused heteroaryl substituted) compounds and their use as s1p1 agonists |
| JP5732182B2 (en) | 2006-10-27 | 2015-06-10 | エルパス・インコーポレイテッドＬｐａｔｈ， Ｉｎｃ． | Compositions and methods for treating eye diseases and symptoms |
| US20100111963A1 (en) | 2006-11-10 | 2010-05-06 | Genentech, Inc. | Method for treating age-related macular degeneration |
| EP2014653A1 (en) * | 2007-06-15 | 2009-01-14 | Bioprojet | Novel dicarboxylic acid derivatives as S1P1 receptor agonists |
| ATE554070T1 (en) | 2007-08-01 | 2012-05-15 | Taisho Pharmaceutical Co Ltd | S1P1 BINDING INHIBITORS |
| CN102239164B (en) | 2008-12-05 | 2013-10-30 | 安斯泰来制药有限公司 | 2H-chromene compound and derivative thereof |
| WO2011050054A2 (en) | 2009-10-23 | 2011-04-28 | Allergan, Inc. | Coumarin compounds as receptor modulators with therapeutic utility |
| KR20120101686A (en) | 2009-11-24 | 2012-09-14 | 알러간, 인코포레이티드 | Novel compounds as receptor modulators with therapeutic utility |
| EP2524693B1 (en) | 2010-01-14 | 2014-05-21 | Sanwa Kagaku Kenkyusho Co., Ltd | Pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability |
| US8273776B2 (en) | 2010-04-16 | 2012-09-25 | Allergan, Inc | Biphenyl oxadiazole derivatives as sphingosine-1-phosphate receptors modulators |
| CN103402986A (en) | 2010-11-24 | 2013-11-20 | 阿勒根公司 | Modulators of S1P receptors |
| JP2013543892A (en) | 2010-11-24 | 2013-12-09 | アラーガン インコーポレイテッド | Indole derivatives as S1P receptor modulators |
| CN103339095A (en) | 2010-12-03 | 2013-10-02 | 阿勒根公司 | Alkyne and alkene derivatives as sphingosine 1-phosphate-1 receptor modulators |
| CN103391782A (en) | 2011-02-02 | 2013-11-13 | 公立大学法人名古屋市立大学 | Medicinal agent for prevention or treatment of diseases associated with intraocular neovascularization and/or intraocular vascular hyperpermeability |
| WO2012142268A1 (en) | 2011-04-14 | 2012-10-18 | Allergan, Inc. | Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators |
| US8513418B2 (en) | 2011-04-18 | 2013-08-20 | Allergan, Inc. | Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators |
| US9000016B2 (en) | 2012-11-05 | 2015-04-07 | Allergan, Inc. | 1,3,4-Oxadiazoles-2-thio derivatives as sphingosine-1 phosphate receptors modulators |
| US8735433B1 (en) | 2012-11-14 | 2014-05-27 | Allergan, Inc. | Aryl oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators |
| US20140235613A1 (en) | 2013-02-20 | 2014-08-21 | Allergan, Inc. | Substituted diaryl azetidine derivatives as sphingosine receptor modulators |
| EP2990055B1 (en) * | 2013-04-26 | 2019-06-05 | Kyoto University | Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it |
| JP2018016911A (en) | 2016-07-28 | 2018-02-01 | 村田機械株式会社 | Analyzer |
-
2019
- 2019-02-01 SG SG11202006255UA patent/SG11202006255UA/en unknown
- 2019-02-01 JP JP2019569604A patent/JPWO2019151470A1/en active Pending
- 2019-02-01 US US16/966,757 patent/US20210113529A1/en not_active Abandoned
- 2019-02-01 KR KR1020207024569A patent/KR20200116953A/en not_active Application Discontinuation
- 2019-02-01 AU AU2019214265A patent/AU2019214265A1/en not_active Abandoned
- 2019-02-01 WO PCT/JP2019/003573 patent/WO2019151470A1/en unknown
- 2019-02-01 CA CA3089952A patent/CA3089952A1/en active Pending
- 2019-02-01 JO JOP/2020/0186A patent/JOP20200186A1/en unknown
- 2019-02-01 BR BR112020015567-5A patent/BR112020015567A2/en not_active IP Right Cessation
- 2019-02-01 MX MX2020007948A patent/MX2020007948A/en unknown
- 2019-02-01 EP EP19747229.3A patent/EP3747471A4/en not_active Withdrawn
- 2019-02-01 CN CN201980010708.6A patent/CN111683682A/en active Pending
- 2019-02-01 RU RU2020128700A patent/RU2020128700A/en unknown
- 2019-02-01 MA MA053098A patent/MA53098A/en unknown
-
2020
- 2020-06-23 IL IL275603A patent/IL275603A/en unknown
- 2020-06-29 PH PH12020551015A patent/PH12020551015A1/en unknown
- 2020-07-14 ZA ZA2020/04327A patent/ZA202004327B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JOP20200186A1 (en) | 2020-07-29 |
| KR20200116953A (en) | 2020-10-13 |
| ZA202004327B (en) | 2022-01-26 |
| IL275603A (en) | 2020-08-31 |
| RU2020128700A (en) | 2022-03-02 |
| PH12020551015A1 (en) | 2021-09-06 |
| MA53098A (en) | 2021-05-12 |
| RU2020128700A3 (en) | 2022-03-02 |
| CA3089952A1 (en) | 2019-08-08 |
| US20210113529A1 (en) | 2021-04-22 |
| MX2020007948A (en) | 2020-12-10 |
| CN111683682A (en) | 2020-09-18 |
| WO2019151470A1 (en) | 2019-08-08 |
| JPWO2019151470A1 (en) | 2021-02-25 |
| EP3747471A4 (en) | 2021-10-27 |
| BR112020015567A2 (en) | 2021-02-02 |
| AU2019214265A1 (en) | 2020-07-23 |
| EP3747471A1 (en) | 2020-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004327B (en) | Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability | |
| EP3749264C0 (en) | Laser therapy for treatment and prevention of eye diseases | |
| IL268327A (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
| EP3823569C0 (en) | Integrated surgical system for treatment in the irido-corneal angle of the eye | |
| PT3545948T (en) | Use of gold cluster or gold cluster-containing substance in preparation of drug for preventing and/or treating glaucoma | |
| IL287758A (en) | Anti-sema3a antibodies and their uses for treating eye or ocular diseases | |
| IL277557A (en) | Sap and peptidomimetics for treatment of eye disease | |
| EP3405159A4 (en) | Treatment and prevention of retinal vascular disease by photocoagulation | |
| IL281773A (en) | Ophthalmic composition for treatment of dry eye disease | |
| EP3481411A4 (en) | Treatment for glaucoma and other eye diseases | |
| IL284344A (en) | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease | |
| IL282504A (en) | Ocular formulations for drug-delivery and protection of the anterior segment of the eye | |
| IL289405A (en) | Personalized treatment of ophthalmologic diseases | |
| SG11202104178TA (en) | Peptides and pharmaceutical compositions for treating eye diseases | |
| EP3691654A4 (en) | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease | |
| SG11202012473UA (en) | Ophthalmic compositions and methods for the treatment of eye disorders | |
| EP3639854A4 (en) | Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof | |
| IL282898A (en) | Ophthalmic compositions and methods for the treatment of skin diseases and eye diseases | |
| HUE061286T2 (en) | Nutraceutical ophthalmic composition for treating diseases of the retina with neovascular component | |
| GB201914516D0 (en) | Treatment of eye disease | |
| SG11202102411WA (en) | Simulated sclera and simulated eyeball | |
| EP3844168A4 (en) | Combination drug formulations for treating patients with cardiovascular disease and associated conditions | |
| FI3752173T3 (en) | Combination of rhodiola and astragalus for the treatment of neurodegenerative diseases | |
| IL291522A (en) | Anti-nrp1a antibodies and their uses for treating eye or ocular diseases | |
| IL279745A (en) | Methods for treating or preventing conformation diseases and methods for drug screening |